Capivasertib added to fulvestrant improves progression-free survival in advanced breast cancer patients
Adding capivasertib to fulvestrant improves the progression-free survival (PFS) in postmenopausal women with oestrogen receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, advanced breast cancer resistant to aromatase inhibitors, concluded Jones et al. (2020) in Lancet Oncology.